TNFRSF9 and plasma cell myeloma: Finally, studies using Vk*MYC demonstrated that: blocking type 1 interferon signaling may inhibit Treg expansion in myeloma (157), antibody to CD137 holds promise as a consolidation treatment in myeloma (158), and HSC transplantion may facilitate both a robust anti-MM CD8 T cell response and a myeloma-specific T cell memory (159) (Figure 6B).